Mostrar el registro sencillo del ítem
dc.contributor.author | Elera-Fitzcarrald, Claudia | |
dc.contributor.author | Reatégui-Sokolova, Cristina | |
dc.contributor.author | Gamboa-Cárdenas, Rocío V. | |
dc.contributor.author | Medina, Mariela | |
dc.contributor.author | Zevallos, Francisco | |
dc.contributor.author | Pimentel Quiroz, Víctor Roman | |
dc.contributor.author | Cucho-Venegas, Jorge M. | |
dc.contributor.author | Alfaro-Lozano, José L. | |
dc.contributor.author | Rodriguez-Bellido, Zoila | |
dc.contributor.author | Pastor-Asurza, César A. | |
dc.contributor.author | Perich-Campos, Risto | |
dc.contributor.author | Alarcón, Graciela S. | |
dc.contributor.author | Ugarte Gil, Manuel Francisco | |
dc.date.accessioned | 2022-02-17T19:23:13Z | |
dc.date.available | 2022-02-17T19:23:13Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/11389 | |
dc.description.abstract | Objectives: This study aims to determine whether the MetS predicts damage accrual in SLE patients. Methods: This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients had a baseline visit and then follow-up visits every 6 months. Patients with ≥ 2 visits were included. Evaluations included interview, medical records review, physical examination, and laboratory tests. Damage accrual was ascertained with the SLICC/ACR damage index (SDI) and disease activity with the SLEDAI-2K. Univariable and multivariable Cox-regression survival models were carried out to determine the risk of developing new damage. The multivariable model was adjusted for age at diagnosis; disease duration; socioeconomic status; SLEDAI; baseline SDI; the Charlson Comorbidity Index; daily dose; and time of exposure of prednisone (PDN), antimalarials, and immunosuppressive drugs. Results: Two hundred and forty-nine patients were evaluated; 232 of them were women (93.2%). Their mean (SD) age at diagnosis was 35.8 (13.1) years; nearly all patients were Mestizo. Disease duration was 7.4 (6.6) years. The SLEDAI-2K was 5.2 (4.3) and the SDI, 0.9 (1.3). One hundred and eight patients (43.4%) had MetS at baseline. During follow-up, 116 (46.6%) patients accrued at least one new point in the SDI damage index. In multivariable analyses, the presence of MetS was a predictor of the development of new damage (HR: 1.54 (1.05–2.26); p < 0.029). Conclusions: The presence of MetS predicts the development of new damage in SLE patients, despite other well-known risk factors for such occurrence. | en_US |
dc.language.iso | eng | |
dc.publisher | SAGE Publications | |
dc.relation.ispartofseries | Lupus | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Metabolic Syndrome | en_US |
dc.subject | Lupus Erythematosus, Systemic | en_US |
dc.subject | Cohort Studies | en_US |
dc.subject | Hospital Guillermo Almenara Irigoyen | en_US |
dc.title | Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1177/09612033211061481 | |
dc.relation.issn | 1477-0962 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |